Since it got its start in 2016, Grail has raised more than $1.5 billion from the likes of Jeff Bezos and Bill Gates along with big names from the pharmaceutical, tech, and healthcare industries, including Johnson & Johnson Innovation, Arch Venture Partners, Amazon, Bristol-Myers Squibb, Celgene, and Merck.
The idea behind its cancer-screening test is to identify the tiny bits of cancer DNA that are hanging out in our blood but are now undetectable. If companies like Grail are successful, they would be the first to pull off a cancer-detecting blood test that works proactively.
The concept is similar to liquid biopsy tests, which use blood samples to sequence genetic information in that blood to figure out how tumors are responding to a certain cancer therapy. In 2017, Grail acquired Cirina, a Hong Kong-based company that is also looking at early cancer detection.
Most recently, the company raised $300 million in a series C round and has started presenting data, including some on early-stage lung cancer detection.
from Trendy News Today https://ift.tt/2R6754I
via IFTTT
0 Comments